Company Overview
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.
Why Investors Should Care
Revenue has grown at a 1227.6% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $4.09M (+1227.6% YoY); net profit $-660.05M.
- Trailing 12 Months Year-on-year growth — revenue +137.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 1227.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 1,227.60% |
| 1 Year: | 137.00% |
Stock Price Performance
| 1 Year: | +79.75% |
| 6 Months: | +87.15% |
| 3 Months: | +91.08% |
| 1 Month: | +0.41% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.96 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 1227.6% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ATAI AtaiBeckley Inc. R3KPHARMA | 7.28 | -2.61 | $2.70B | 0.00% | - | - | 1,227.60% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 1.55M | 954.00K |
| Operating Income | -20.37M | -30.90M |
| Net Income | -26.43M | -29.78M |
| Diluted EPS | -0.15 | -0.08 |
| R&D Expense | - | 600.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 308.00K | 4.09M |
| Operating Income | -102.69M | -644.06M |
| Net Income | -149.27M | -660.05M |
| Diluted EPS | -0.93 | -2.91 |
| R&D Expense | 900.00K | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 159.39M | 292.72M |
| Total Equity | 116.30M | 221.87M |
| Cash & Equivalents | 17.50M | 85.30M |
| Long Term Debt | 14.13M | 0 |
| Total Liabilities | 42.83M | 70.72M |
| Current Liabilities | 24.95M | 23.48M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -82.44M | -102.67M |
| Investing Cash Flow | 59.17M | -109.13M |
| Financing Cash Flow | 5.37M | 269.48M |
| Capital Expenditure | -6.00K | -901.00K |
| Free Cash Flow | -82.44M | -103.58M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | -33,341.2% | -15,751.1% |
| Net Margin % | -48,464.0% | -16,142.0% |
| ROE % | -128.4% | -297.5% |
| ROCE % | -76.4% | -239.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 6.90% | 25.57M | $187.97M |
| 2 | Deep Track Capital, Lp | 3.89% | 14.42M | $105.97M |
| 3 | Vanguard Capital Management LLC | 3.17% | 11.75M | $86.34M |
| 4 | State Street Corporation | 2.23% | 8.29M | $60.91M |
| 5 | Geode Capital Management, LLC | 1.87% | 6.93M | $50.96M |
| 6 | Adage Capital Partners GP L.L.C. | 1.52% | 5.64M | $41.47M |
| 7 | UBS Group AG | 1.19% | 4.42M | $32.52M |
| 8 | Vanguard Portfolio Management LLC | 1.11% | 4.11M | $30.18M |
| 9 | Morgan Stanley | 1.04% | 3.84M | $28.25M |
| 10 | Candriam S.C.A. | 0.82% | 3.04M | $22.34M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ATAI
Why Is ATAI Stock Soaring 59% After-Hours? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQZ21TbUplOGM4VnM2dFQ1X2kydFJJdlRfZGxOSkRORUdmcWVqdExVMG95ZGNBUzRmSkQ4SDRrYzUzYjh1d3ZkcDhQbVRLMzdBbktaYkp1QkdnQjBmdmZqMC10OFpScDhVUzJVUmlMUDh2dl9ycXdzbzRvV1ZrM08tMFlQQTVlQXZGLThKWE…
Shareholders clear Lilly merger for AtaiBeckley (ATAI), with closing still subject to conditions - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxORHllZFlnbm1ITzFEX3ZmQXRlNS1mZEgyWGJpUVN6UjhfQUFBTnU0U0FLNktyc1BaZmJvM1BKaHZFejFYY1Z3SEJMYTR1Z216VXVXa1FsMnQ5WnFPdUVNNjd1cDRlQlAwb1pZOFZtQzE1bEk4LS1PLTJXUVY5NFBXMUI4UWFaVFFESXdGQl…
Atai Beckley (NASDAQ:ATAI) Clears Minervini Trend Template and High-Growth Momentum Screen - ChartMill
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxNR3pncUQ2WG1HLUdtMlN0bExWZjFudVhZemlKZGRCRGpRa2lhek9KN1dZcndidGc3WUhZV3cwbDRVd1NUdTgxTVFBaDlvb1RJaGtFYjU2Sm85MFBpLXU3WmZqQ2R5S241THk0QUdfcnF0S3pUY1hUVmlRVFJnZ0JITi1iWkpSZC1yZGJ1R0…
AtaiBeckley(ATAI) Stock Options Chain | Quotes & News - Moomoo
<a href="https://news.google.com/rss/articles/CBMiwgJBVV95cUxNQVRjc003MzJaRmZWa01rLUx4MEl3dWZlVGUwVGdLVFNyMHctS1ZuWnJnWU00d0NxMzZwYVhvd1NlZTJDUFc2U19IdTB6dnI2aHJyX2pzZTB3TkpxdU1CVm4ySDMxckFsb242RUNMZE8wU2U1SGk3N09iVFBTNXZSdFdLemJPSEtRWUV5Rk…
Is AtaiBeckley Inc (ATAI) Stock Outpacing Its Medical Peers This Year? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQZ3NyZUNueDFacVNaLVJHYmRLSkd4eU9SUzFYMlRUZWVDRjE1RWM2RjhZYldBRGx4eFItUUttZDJOcWhfajZoTUxMMllCci1BdmRUcERCekpfNmhxdkFSNmYwNnVSdEwtT1dDQUtOWWJ4YkRjaUw2UlZrOERVcWM5a1lKbGdMTHRkREp0a0…
Technical Reactions to ATAI Trends in Macro Strategies - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxNaVR2UU5QRno3dExjQmxxS0VKQTV0eFgzX3VwS0xzWmRxaDBoWlJCdFphY0N5c05qZ1VLSHFLSGdlb2V4bDVnSmJKbUlORzlsRXNMT29sSmJ0SmxDeTFpNk1xQ3pKeVMzakZ3UHlJLXgyYVk3WGh1VmZYRklfNks0WG14NWc1RGJwcVFmWm…
ATAI — Frequently Asked Questions
What is the current share price of AtaiBeckley Inc. (ATAI)?
As of 2026-09-19 21:16 PDT, AtaiBeckley Inc. (ATAI) trades at $7.28 on NasdaqGM. Its 52-week range is $3.35 to $7.44.
What is the market capitalisation of ATAI?
AtaiBeckley Inc. (ATAI) has a market capitalisation of $2.70B on NasdaqGM.
What is the P/E ratio of ATAI?
ATAI trades at a trailing price-to-earnings (P/E) ratio of -2.61. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 15.25.
Is ATAI a good stock to buy?
This page provides a data-driven analysis of AtaiBeckley Inc. (ATAI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.